Dendreon Corp (NASDAQ:DNDN)

CAPS Rating: 2 out of 5

A biotechnology company focused on the discovery, development and commercialization of novel therapeutics that harness the immune system to fight cancer.

Recs

0
Player Avatar AKHENATENX (< 20) Submitted: 8/9/2011 6:13:12 PM : Outperform Start Price: $10.65 DNDN Score: -47.85

Sell off over done

Report this Post Reply

Featured Broker Partners


Advertisement